论文部分内容阅读
目的 探讨 CD44 V6 在肺癌中的表达及其临床价值。方法 采用免疫组化 ( SP法 )检测了 45例非小细胞肺癌 ( NSCL C)和 16例小细胞肺癌 ( SCLC)中 CD44 V6 分子的表达情况。结果 13 1例 NSCL C呈现 CD44 V6 阳性反应 ,阳性率为 68.9% ,而 SCLC则全部阴性 ( P<0 .0 1)。 2在鳞、腺癌中 ,有淋巴结转移组中的 CD44 V6 阳性率高于无淋巴结转移组 ( P<0 .0 5 )。结论 CD44 V6 在 NSCL C转移过程中可能起重要作用 ,并可作为一个预后指标 ,而 SCL C的转移则不依赖于 CD44 V6 的介导 ;而且 CD44 V6 可作为一种新的标志物 ,用于鉴别肺癌的组织学类型。
Objective To investigate the expression of CD44 V6 in lung cancer and its clinical value. Methods The expression of CD44 V6 in 45 non-small cell lung cancer (NSCLC) and 16 small cell lung cancer (SCLC) was detected by immunohistochemistry (SP method). Results 13 cases of NSCL C showed CD44 V6 positive reaction, the positive rate was 68.9%, while the SCLC was all negative (P <0.01). In squamous cell carcinoma and adenocarcinoma, the positive rate of CD44 V6 in lymph node metastasis group was higher than that in non-lymph node metastasis group (P <0.05). Conclusions CD44 V6 may play an important role in the metastasis of NSCL C and may be used as a prognostic marker, whereas SCL C metastasis is independent of CD44 V6. CD44 V6 may serve as a new marker for Identification of histological types of lung cancer.